Allergan reports Memantine Phase 3 clinical trial results
Allergan, Inc. has reported findings from the second Phase 3 clinical trial examining the safety and efficacy of oral Memantine as a treatment for glaucoma.
Although the study showed that the progression of disease was significantly lower in patients receiving the higher dose of Memantine compared to patients receiving the low dose of Memantine, there was no significant benefit compared to patients receiving placebo. Therefore, the study failed to meet its primary endpoint and to sufficiently replicate the results of the first Phase 3 trial.
While additional analyses are ongoing, the company does not believe that these analyses will support an approval of the drug.
Last reviewed on April 05, 2011